Platinum Priority – Prostate CancerEditorial by Chris Bangma and Monique Roobol on pp. 908–909 of this issueActive Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions
Introduction
Prostate cancer (PCa) screening reduces advanced disease and PCa-specific death [1], [2], but also leads to “overdiagnosis” and overtreatment of indolent tumors [3], [4]. Conservative management is increasingly utilized for favorable-risk PCa to delay or avoid aggressive treatment and potential side effects [5]. Prior comparative-effectiveness models have confirmed that this is a valid strategy for certain patients [6], [7], [8], with improved quality of life (QOL) and reduced initial resource utilization [9].
Despite agreement on the importance of conservative management to preserve screening benefits and reduce overtreatment [10], there is no consensus what to do next [11], [12]. Conservative management encompasses two very different strategies: “watchful waiting” (WW) without curative intent and “active surveillance” (AS) with serial testing for “disease progression” to offer selective delayed treatment with curative intent. No randomized trials have compared benefits and harms between WW and contemporary AS. Furthermore, for patients choosing AS, there is no consensus on the type, frequency, or sequence of follow-up tests to monitor for disease progression [11]. Thus, the objective of this clinical decision analysis is to compare life expectancy and quality-adjusted life expectancy between WW and different AS protocols for US men ≥50 yr.
Section snippets
Patients and methods
We developed a state-transition Markov model to compare different strategies of conservative management for a cohort of US men diagnosed with clinically localized PCa who chose conservative management. Markov models represent a hypothetical cohort moving among predefined health states that are mutually exclusive and collectively exhaustive [13]. Our model starts when the patient is diagnosed with PCa and begins conservative management. We used this model to evaluate two different outcomes: life
Main base case analysis
Table 2 shows the base case results of the decision analysis. In a cohort of men starting at age 50 with low-risk PCa undergoing conservative management, AS using the Johns Hopkins strategy yielded more LYs compared with WW (35.21 vs 34.55 LYs, or a difference of 0.66 life-years; Table 2). Lifetime risks of PCa death and metastasis were, respectively, 5.42% and 6.40% with AS versus 8.72% and 10.30% with WW. Men on AS had a 50% lifetime risk of undergoing radical treatment.
Using the outcome of
Discussion
AS extends life more than WW, particularly for men with higher-risk disease with a greater risk of metastasis. However, intensive follow-up protocols with frequent rebiopsy and use of radical treatment for men with grade reclassification may reduce QOL. Extending the interval between biopsies up to 5 yr led fewer men to receive radical treatment, with a small reduction in incremental LYs and QALYs. Time preferences and duration of QOL decrements from treatment side effects also had a
Conclusions
AS extends life more than WW, but this is partly offset by the decrement in QOL since a substantial proportion ultimately undergo radical treatment. Patient preferences had a significant influence on model results, and further research is warranted on how to optimally incorporate preference assessment into clinical practice.
References (56)
- et al.
Active surveillance versus surgery for low risk prostate cancer: a clinical decision analysis
J Urol
(2012) - et al.
Active surveillance for low-risk prostate cancer worldwide: the PRIAS study
Eur Urol
(2013) - et al.
Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer
J Urol
(2013) - et al.
Complications after prostate biopsy: data from SEER-Medicare
J Urol
(2011) - et al.
Impact of multiparametric endorectal coil prostate magnetic resonance imaging on disease reclassification among active surveillance candidates: a prospective cohort study
J Urol
(2012) - et al.
Magnetic resonance imaging for predicting prostate biopsy findings in patients considered for active surveillance of clinically low risk prostate cancer
J Urol
(2012) - et al.
From QOL to QALYs: comparing nononcologic outcomes in prostate cancer survivors across treatments
Urol Oncol
(2017) - et al.
Conditional probability of reclassification in an active surveillance program for prostate cancer
J Urol
(2015) - et al.
Risk of Gleason grade inaccuracies in prostate cancer patients eligible for active surveillance
Urology
(2012) - et al.
Gleason upgrading with time in a large prostate cancer active surveillance cohort
J Urol
(2015)